Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer
Clinical trial NCT02959749 · COMPLETED
Trial details
- NCT number
- NCT02959749
- Sponsor
- Qingdao Central Hospital
- Status
- COMPLETED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-08-01
- Primary completion
- 2017-10-01
- Enrollment
- 147
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.